# An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

> **NCT00399048** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 140 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **DRUG:** OROS hydromorphone HCL ; OxyContin

## Key facts

- **NCT ID:** NCT00399048
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2001-05
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399048, "An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00399048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*